PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.86
AASLD 2021,
“CT-859, A NOVEL FULLY BIASED UNIMOLECULAR DUAL GLP-1 AND GIP RECEPTOR MODULATOR RESOLVES NASH AND FIBROSIS, DECREASES TUMORS, AND IMPROVES SURVIVAL IN A MOUSE NASH MODEL” Carmot Therapeutics
No.85
AASLD 2021,
“ECC0509, A NOVEL PERIPHERALLY DISTRIBUTED AND SELECTIVE SEMICARBAZIDE-SENSITIVE AMINO OXIDASE (SSAO) INHIBITOR FOR NASH TREATMENT” Eccogene
No.84
EASL the International Liver CongressTM 2021,
“First in class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histological features of non-alcoholic steatohepatitis (NASH) in vitro and in vivo” Enzychem Lifesciences